| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Guest Access | Sign In via User Name/Password
|
|
|
|||||||
Guest Access | Sign In via User Name/Password |
|||||||||
* From the Department of Allergy, Hospital Ramón y Cajal, Madrid, Spain.
Correspondence to: Miguel Hinojosa, MD, Hospital Ramón y Cajal Department of Allergy Carretera de Colmenar, Km 9,100 28034, Madrid, Spain; e-mail: mhm01m{at}lsaludalia.com.es
Background: In 5 to 10% of adult patients with asthma, aspirin (acetylsalicylic acid [ASA]) and most other nonsteroidal anti-inflammatory drugs (NSAIDs) precipitate acute asthmatic attacks. Therefore, choosing an alternative anti-inflammatory agent for patients with adverse reactions to an NSAID is a common problem in clinical practice. The discoveries that cyclooxygenase (COX)-2 is an inducible form of COX that is involved in inflammation and that COX-1 is the major isoform responsible for the production of prostaglandins have provided a reasonable basis for the development of specific COX-2 inhibitors as a new class of anti-inflammatory agents.
Objective: The purpose of this study was to demonstrate that rofecoxib, a specific inhibitor of COX-2, does not cause asthmatic attacks in patients with ASA and/or other NSAID-induced asthma.
Methods: We studied 40 patients, all of whom had experienced asthma induced by at least two different NSAIDs. The patients were challenged in a single-blind manner with different doses of rofecoxib on 3 different days, until either the therapeutic dose of 25 mg or intolerance was reached. Each patient was rechallenged with 25 mg of rofecoxib 7 days later if no evidence of intolerance had been observed previously.
Results: Rofecoxib, 25 mg, was proven to be well tolerated in all 40 patients with ASA-induced and NSAID-induced asthma.
Conclusion: Our study appears to demonstrate that rofecoxib is a suitable NSAID for treatment of patients with ASA and/or other NSAID-induced asthma.
Key Words: aspirin-induced asthma • asthma • cyclooxygenase enzyme • cyclooxygenase-2 inhibitors • rofecoxib
This article has been cited by other articles:
|
|
 |
|
  M. I. Kidon, L. W. Kang, C. W. Chin, L. S. Hoon, Y. See, A. Goh, J. T. P. Lin, and O. M. Chay Early Presentation With Angioedema and Urticaria in Cross-reactive Hypersensitivity to Nonsteroidal Antiinflammatory Drugs Among Young, Asian, Atopic Children Pediatrics, November 1, 2005; 116(5): e675 - e680. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. SPINK, S. BAHN, and R. GLICKMAN Clinical implications of cyclo-oxygenase-2 inhibitors for acute dental pain management: Benefits and risks J Am Dent Assoc, October 1, 2005; 136(10): 1439 - 1448. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. L Marshall Angioedema Associated with Aspirin and Rofecoxib Ann. Pharmacother., May 1, 2005; 39(5): 944 - 948. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Zembowicz, L. Mastalerz, M. Setkowicz, W. Radziszewski, and A. Szczeklik Safety of Cyclooxygenase 2 Inhibitors and Increased Leukotriene Synthesis in Chronic Idiopathic Urticaria With Sensitivity to Nonsteroidal Anti-inflammatory Drugs Arch Dermatol, December 1, 2003; 139(12): 1577 - 1582. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
P. M West and C. Fernandez Safety of COX-2 Inhibitors in Asthma Patients with Aspirin Hypersensitivity Ann. Pharmacother., October 1, 2003; 37(10): 1497 - 1501. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 N. M. Gajraj Cyclooxygenase-2 Inhibitors Anesth. Analg., June 1, 2003; 96(6): 1720 - 1738. [Full Text] [PDF]
|
|
|
|
 |
|
 Is Rofecoxib Safe in Aspirin-Sensitive Asthmatics? Journal Watch Emergency Medicine, August 28, 2002; 2002(828): 7 - 7. [Full Text]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
